Mendus AB (publ) (STO: IMMU)

Sweden flag Sweden · Delayed Price · Currency is SEK
8.79
+0.32 (3.78%)
Aug 30, 2024, 5:21 PM CET
41.77%
Market Cap 442.66M
Revenue 31.60M
Net Income -141.42M
Shares Out 50.36M
EPS -3.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 46,160
Open 8.47
Previous Close 8.47
Day's Range 8.47 - 8.81
52-Week Range 6.04 - 16.38
Beta 1.13
Analysts n/a
Price Target n/a
Earnings Date Nov 8, 2024

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 28
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMU
Full Company Profile

News

There is no news available yet.